

Index

a

- abalone mushroom 212
- Acer pseudoplatanus* 151
- acetylcholinesterase inhibitors 101, 114
 - Amaryllidaceae 304
 - amyloid beta (A β) cascade
 - hypothesis 93
 - anti-AD drugs 93
 - Apocynaceae 304
 - APP 93
 - Buxaceae 305
 - donepezil 299
 - extracellular senile plaques 297
 - huperzine 299
 - intracellular neurofibrillary tangles (NFTs) 298
 - Liliaceae 306
 - Lycopodiaceae 305
 - Magnoliaceae 304
 - mechanism of action 298
 - Menispermaceae 303
 - Nelumbonaceae 303
 - neurotoxic A β peptide 297
 - non-alkaloid acetylcholinesterase inhibitors 306–309
 - Papaveraceae 303
 - presenilins 1 and 2 297
 - prodromal mild cognitive impairment 298
 - Rutaceae 302
- Achillea biebersteinii* 143
- active targeting 11
- adenomatous polyposis coli (APC) gene 169
- adenosine 213
- Agnuside 179
- alkaloid(s) 116–118
 - hypoglycaemic natural compounds 147
- alkylsalicylic acids 212
- Amaryllidaceae 304
- α -amylase 141
 - hypoglycaemic effects 136
 - inhibition 146
 - inhibitory activity 139, 142
- $\alpha\beta$ -epoxyketone 24
- α -glucosidase 140, 146
 - hypoglycaemic effects 137
 - inhibitory effects 140–141
- Amaranthus caudatus* 147
- Amaryllidaceae 304
- 2-Amino-5-nitro-*N*-hydroxybenzamidine 285
- 4-aminoquinoline-1,3,5-triazine conjugates 286, 289
- 4-aminoquinoline-1,3,5-triazine hybrids 287
- amyloid beta (A β) cascade
 - hypothesis 93
- amyloid precursor protein (APP) 93
- Anacardiaceae 309
- angiotensin carboxypeptidase inhibitors 4
- angiotensin converting enzyme inhibitors
 - angiotensin-receptor blockers and calcium channel blockers 49
- antihypertensive drugs 48

- angiotensin converting enzyme
 inhibitors (*contd.*)
 chloride ion activation 48
 natural products
 phenolic compounds 50
 protein derived peptides 55–58
 prehypertensive stage 49
 RAAS pathway 49
 vasoconstriction-volume model 48
 zinc-dependent metallopeptidase 47
Anisotes trisulcu 147
 anthelmintic agents 241
 anthocyanidins 141
 anthocyanins 140–141
 anthraquinones 114–116
 antibody drug conjugates
 (ADCs) 11, 32
 antidiabetic agents 136
 antifungal proteins 210
 anti-HIV natural products 209
 HIV-1 integrase inhibitors 214
 reverse transcriptase inhibitors
 alkylsalicylic acids and
 bilobols 212
 antifungal proteins 210
 cathelicidins 210
 defensins and defensin-like
 antifungal peptides 210
 HIV-1 protease inhibitor 213
 illimaquinone 212
 laccases and ribonucleases 212
 lactoferrin 211
 lectins 211
 polysaccharides and
 polysaccharopeptides 212
 proteases and protease
 inhibitors 211
 ribosome-inactivating proteins
 (RIPs) 209–210
 antihypertensive drugs 48
 antimycin 234
 apigenin 10
Aplysilla 83
 Apocynaceae 304
 apratoxin A 32
Aralia taibaiensis 147
 Archazolid A 12
Arnica montana 180
 ascochlorin 234
Aspergillus 240
 asteltoxin 237
 astragaloside-IV 119
Auricularia polytricha 123
 aurilide 34
 aurovertin 237
 axinelline A 182
b
Bacillus amyloliquefaciens 210
 baicalein 170
 baicalin 95
Balanophora involucreta 98
 BChE inhibition 302–303
 benzodiazepines scaffold 2
 benzoquinones 114–116
 berberine 148, 171
Berberis lyceum 148
 bergamot essential oil 10
 β -amyloid 263
 β blockers 49
 β cells 135
 β -secretase 1 (BACE1) inhibitors 29,
 30, 94
 alkaloids 116–118
 anti-BACE1 activity 110
 benzoquinones and
 anthraquinones 114–116
 biflavonoids 98–100
 blood brain barrier (BBB)
 permeability 94
 catechins 102–103
 chalcones 100–102
 chromone glycosides 104
 coumarins 112–114
 CTS-21166 94
 curcumin derivatives 110
 dihydroflavonoids 96–98
 fatty acid 121
 flavonoids
 anti-oxidative and anti-
 inflammatory activities 95
 baicalin 95
 5, 7-dihydroxyl substituents 95
 luteolin 95

- prenyld flavonoids 96
 - isoflavonoids 102
 - lignans 120
 - natural products extracts 122–124
 - oral bioavailability 94
 - peptide inhibitors 121
 - peptidomimetics 94
 - phenol acids 105–106
 - polyphenols 108
 - prenylated flavanones 98
 - saccharides 121
 - simple phenol derivatives 107
 - stilbenes and derivatives 110–112
 - structural analysis technologies 125
 - tannins 106–107
 - terpenes 118–120
 - xanthenes 104
- biaryl piperazines 94
- bidesmosidic oleanolic acid
 - saponins 146
- biflavonoids 98–100
- bilobols 212
- BIOPEP database 55
- biosynthetic process 2
- biotechnological approaches 5
- bisebromoamide 32
- bolinaquinone 82
- brentuximab vedotin 11
- bromophenols vidalol A 85
- bromophenols vidalol B 85
- bryostatin-1 263
- bryostatins 9
- Bugula neritina* 263
- butyl gallate 164
- butyryl cholinesterase (BChE)
 - inhibitory assays 114
- Buxaceae 305
- c**
 - Cacospongia mollior* 78
 - calcium-dependent PLA₂ 70
 - canagliflozin 12
 - capillary electrophoresis (CE) 9
 - captopril 49, 51
 - carmaphycins A 23
 - catechins 94, 102–103
 - cathelicidins 210
 - cathepsin inhibitors 28–30
 - cathepsin L 30
 - celastrol 179
 - cell-free system 124
 - C-glycosylation 95
 - chalcones 100–102
 - chebulagic acid 164, 172
 - chenopodiaceae 306
 - chlorogenic acid 142
 - 2-chloro-4-nitrophenyl α -maltotrioxide
 - degradation 139
 - chromone glycosides 104
 - chronic myeloid leukemia (CML) 169
 - citreoiviridin 237
 - Clavicocona pyxidata* 123
 - Combretaceae 309
 - computational screenings 2
 - p*-coumaric acid 108
 - coumarins 112–114
 - counter-current chromatography
 - (CCC) 9
 - COX-2-5-LOX dual inhibitors
 - (CLOXIBs) 163
 - C-phycoerythrin 183
 - Cryptotethya crypta* 256
 - Curcuma longa* 172
 - curcumin 10, 109, 172–173
 - cyanidin 140
 - cyanobacteria 8
 - cyclodextrins 10
 - cyclooxygenase 166
 - cytarabine triphosphate 256
- d**
 - daedalol 119
 - darunavir 12
 - 1, 2-*N*-deethylphenyl-isohericerin 106
 - diacylglycerol acetyl-transferase
 - (DGAT) 260
 - dietary proteins 56
 - difurano-sesterterpenes 83
 - dihydrochalcones 101
 - dihydroflavonoids 96–98
 - dihydrofolate reductase (DHFR)
 - inhibitors 286–290
 - dihydropteroate synthase (*Pfdhps*) 277
 - Dioscorea dumetorum* 149

- dioscoretine 149
- diterpenoid dihydroajugapitin 308
- diuretics 49
- docosahexaenoic acid (DHA) 168
- dolastatins 10 15, 31
- donepezil 299
- drug bioavailability 11
- Dysidea avara* 82

- e**
- Ecklonia cava* 152
- eicosanoid(s) 71
- eicosanoid synthesis
 - cyclooxygenase 166
 - cytochrome P450 (CYP)-dependent monooxygenases 166
 - inflammation and cancer
 - COX, role of 168–169
 - CYP-dependent monooxygenases 170
 - LOX, role of 169–170
 - PLA₂ 167
 - lipoxygenases 166
 - natural products derived anti-inflammatory agents
 - baicalein 170
 - berberine 171
 - chebulagic acid 172
 - curcumin 172–173
 - ellagic acid 173
 - epigallocatechin-3-gallate (EGCG) 174
 - eugenol (4-allyl-2-methoxyphenol) 174
 - fisetin 174–175
 - gallic acid (GA) 175
 - genistein 175
 - guggulsterone 176
 - piperine 176–177
 - quercetin 177
 - resveratrol 178
 - silibinin 178–179
 - terpenoids 179–180
 - triptolids 180–181
 - ursolic acid 181–182
 - phospholipases 165
 - PLA₂ activation 164
- electron transport chain (ETC) inhibitors
 - anthelmintic agents 241
 - anti-tumour properties 244 and diabetes 241
 - fungicides 239–240
 - insecticides 240 and neurotoxicity 245–246 and old marketed drugs 246
 - pesticidal and insecticidal activity 241
 - protozoan parasites 241
 - therapeutic strategy in cancer 242
- ellagic acid 173
- ellagitannins 150
- enzyme inhibitors
 - angiotensin carboxypeptidase inhibitors 4
 - galanthamine 4
 - natural compounds/derivatives 4
- epiberberine 116
- epigallocatechin-3-gallate (EGCG) 107, 124, 174
- eugenol (4-allyl-2-methoxyphenol) 174
- extracellular senile plaques 297

- f**
- falcipain(s) 28
- falcipain (FP-2) inhibitors 27–28, 278–284
- Fasciospongia cavernosa* 82
- fatty acid 121
- ferulic acids 141
- fibroblast growth factor 33
- Ficus bengalensis* 141
- fisetin 174–175
- flavonoids 50
 - anti-oxidative and anti-inflammatory activities 95
 - baicalin 95
 - 5, 7-dihydroxyl substituents 95
 - hypoglycaemic natural compounds 139–141
 - luteolin 95
 - prenyld flavonoids 96
- fluorescence based assay methods 124

- fluorescence resonance energy transfer (FRET) 124
- 4-*O*-methyl gallic acid (4-OMGA) 175
- 4-*O*-methylhonokiol 120
- fungicides 239–240
- furanocoumarins 113
- furanosesterterpene 83
- g**
- galactosylsphingosine (psychosine) 236
- galanthamine 4
- gallic acid (GA) 106, 175
- gallinamide A 27
- γ -lactam 106
- genistein 175
- Ginkgo biloba* 122
- Ginsenoside Rg1 119
- glycogen phosphorylase α (GP α) inhibition assay 150
- glycosides 140
- C-glycosylation 95
- Glycyrrhiza uralensis* 100
- Gly-Trp-Trp-Glu 121
- gnetin H 110
- gracilins 119
- grassystatin A 28
- groenlandicine 116
- guggulsterone 176
- h**
- halogenation 69
- Herpes Simplex Virus (HSV-1) 172
- hetero-chitooligosaccharides 121
- high-performance liquid chromatography (HPLC) 9
- Hippiospongia metachromia* 82
- hispidin 108
- histone deacetylase inhibitors largazole 20–22 santacruzamate A 22–23
- HIV-1 integrase inhibitors 214
- HIV-1 protease inhibitor 213
- Holarrhena antidysenterica* 304
- homogeneous time-resolved fluorescence (HTRF) 124
- human epidermal growth factor receptor 3 (HER3) 34
- human umbilical vein endothelial cells in culture (HUVEC) 172
- Hunteria umbellata* (HU) 147
- huperzine 299
- hydroperoxy eicosatetraenoic acids (HPETEs) 166
- 5-hydroperoxyeicosatetraenoic acid 72
- 4-hydroxynonenal 236
- hypertension (HTN) angiotensin converting enzyme inhibitors angiotensin-receptor blockers and calcium channel blockers 49 antihypertensive drugs 48 chloride ion activation 48 natural products 50–55 prehypertensive stage 49 RAAS pathway 49 vasoconstriction-volume model 48 zinc-dependent metalloproteinase 47
- blood pressure regulation, RAAS 46–47
- classification 45
- definition 45
- incidence 45
- metabolic disorders 45
- risk factor 45
- hypoglycaemic natural compounds alkaloids 147–150 flavonoids 139–141 phenolic acids 141 tannins, ellagitannins 150 terpenoids 142–147
- hypoxanthine and guanine-9-[2-hydroxy-3-(phosphonmethoxy)propyl] derivatives 291
- hypoxanthine-guanine-xanthine phosphoribosyl transferase 277
- inhibitors 290
- i**
- illimaquinone 212
- indole alkaloid vindogentianine 150

- inflammatory process
 bacteria and protozoa 70
 endogenous/exogenous
 mediators 69
 phospholipase A₂ (PLA₂) inhibitors
 bacteria and protozoa 70
 calcium-dependent sPLA₂ 70
 eicosanoids 71
 5-hydroperoxyeicosatetraenoic
 acid 72
 radiometric assays/
 immunoassay 72
 role of 71
 sPLA₂ 71
 sponge-derived
 metabolites 72–83
 Inhibitors of Apoptosis Proteins (IAP)
 family 182
 interleukin-1 β (IL-1 β) 168
 intracellular neurofibrillary tangles
 (NFTs) 298
 iodo-starch method 139
Iridaceae 308
 isoflavones 243
 isoflavonoids 102
 Isohericerin 106
 Iso-oenothien C 151
- k**
 kallikrein–kinin system (KKS) 49
 kojic acid (5-hydroxy-
 2-hydroxymethyl-4-
 pyranone) 184
- l**
 laccases 212
 lactoferrin 211
 Laragh's hypothesis 48
 largazole 8, 20–22
 lectins 211
 leoheteronin A 307
 leopersin G 307
 leucine-histidine-leucine-proline-
 leucine (LHLPLP) 56
 leukemia stem cells (LSCs) 169
 leukotriene B₄ (LTB₄) 170
 lignans 120
 Liliaceae 306
 liposomes 10
 lipooxygenases 166
Lithoplocamia lithistoides 264
 lobaric acid 185
 lonidamine 243
 Lovaza[®] 260
 LOX, role of 169–170
Luffariella 73
 lupanine 149
 2,3-*seco*-20(29)-Lupene-2,3-dioic
 acid 145
 lurbinededin 261
 luteolin 95, 139
Lycopodiaceae 305
Lyngbya confervoides 28
 lyngbyastatin 7 26
- m**
Macaranga tanarius 150
 Magnoliaceae 304
Magnolia grandiflora 180
Magnolia officinalis 123
Mangifera indica 151
 Marfey's method 29
 marine actinomycetes 6
 marine cyanobacteria
 actin and microtubule filaments
 bisbromoamide 32
 dolastatins 10, 15, 31
 cellular targets 19
 dolastatin 10 and TZZT-1027 20
 histone deacetylase inhibitors
 largazole 20–22
 santacruzamate A 22
 prohibitin inhibitors 34
 protease enzymes
 β -secretase 1 (BACE1)
 inhibitors 30
 cathepsin inhibitors 28–30
 falcipain inhibitors 27
 serine protease inhibitors 24–26
 proteasome inhibitors 23
 protein kinase C modulators 30–31
 Sec61 protein translocation channel
 inhibitors 32
 sodium channels modulators 35

- marine-derived candidates 261–264
- marine-derived drugs
- base excision repair (BER)
 - mechanism 258
 - cytarabine 256
 - dolastatin 10 259
 - NF- κ B activity 260
 - polo-like kinase 1 (PLK1) inhibitor BI 2536 259
 - polyether macrolide halichondrin B 259
 - protein kinase C (PKC) 256
 - semisynthetic process 258
 - trabectedin effects 258
 - transcription-coupled nucleotide repair
 - mechanisms (TC-NER) 258
 - ziconotide 261
- marine sponges
- anti-psoriasis sesquiterpene hydroquinone avarol 82
 - Aplysilla* 83
 - bioactive pyridinium alkaloids 81
 - bolinaquinone 82
 - Cacospongia mollior* 78
 - cacospongionolide B 82
 - cacospongionolide E 82
 - difurano-sesterterpenes 83
 - Dysidea sp.* 81
 - dysidine 82
 - furanosesterterpene 83
 - Luffariella* 73
 - manoalide 73
 - sesquiterpene lactone cavernolide 82
- membrane-associated prostaglandin E synthase (mPGES) 168
- Menispermaceae 303
- metabolic disorders 45
- metformin 12, 241, 243
- microencapsulation 10
- mitochondrial electron transport chain (ETC)
- ATP synthase 227
 - cell energy generation 225
 - complex II 227
 - complex I inhibitors
 - acetogenins (ACGs) 228
 - annonaceous ACGs 231–232
 - bacteria 228
 - Bis-THF ACGs 232
 - fungi 230
 - isodesacetyluvaricin 233
 - linear and epoxy ACGs 231
 - mono-THF ACGs 232
 - myxobacteria 230
 - pericidins 230
 - rotenone 228
 - complex II inhibitors 233–234
 - complex III inhibitors 227, 234–235
 - complex IV inhibitors 235–237
 - complex V inhibitors 237–239
 - mammalian mitochondrial cytochrome c oxidase 227
 - NADH-ubiquinone oxidoreductase 226
 - therapeutic, agrochemical and toxicological implications 239
 - toxic compounds 225
- mitochondrial permeability transition pore (MTP) 244
- mitogen-activated protein kinase (MAPK) 256
- monomethyl auristatin E (MMAE) 32
- Moringa stenopetala* 150
- Myristicaceae* 309
- myxobacteria 230
- n**
- 1, 4-naphthoquinones 114
- natural compounds 136
- natural products *see also* anti-HIV natural products; β -secretase 1 (BACE1) inhibitors
- antibody-drug conjugate 11
 - biological functions 1
 - biological properties 2
 - biosynthetic process 2
 - biotechnological approaches 5
 - chemical and structural diversity 1
 - chemical traits 2
 - combinatorial screening collections 1

- natural products (*contd.*)
 drug bioavailability 11
 intellectual property 5
 lack of high-quality libraries 5
 lack of novelty 5
 Lipinski's rule 9
 liposomal aqueous compartment 10
 marine organisms/extremophiles 5
 marine origin 182–183
 microencapsulation 10
 microorganisms 183–185
 nanotechnology 9
 “privileged” scaffold 2
 robust analytical techniques and instrumentation 5
 secondary metabolites 5
 solid dispersion 10
 solid lipid nanoparticles 10
 targeting strategies 11
 technologies and methods
 analgesic mechanism 6
 biosynthetic pathways 8
 bryostatin biosynthetic genes 9
 fermentation 8
 hyphenated spectroscopy technologies 9
 marine drugs 6
 marine environment 6
 metagenomics and microbial genomics 5
 metagenomics approaches 9
 purification and characterization process 9
 secondary metabolites 6
 separation technologies 9
 structure-activity relationship (SAR) studies 8
 three-dimensional conformation 2
 natural products database (NPD) 278
 neferine 116
 Nelumbonaceae 303, 309
 neurotoxicity 245–246
N-methyl- *D*-aspartate (NMDA) receptor inhibitor 299
 non-alkaloid acetylcholinesterase inhibitors
 Anacardiaceae 309
 Chenopodiaceae 306
 Clusiaceae 307
 Combretaceae 309
 Fabaceae 307
 Gentianaceae 307
 Iridaceae 308
 Lamiaceae family 307
 Moraceae 308
 Myristicaceae 309
 Nelumbonaceae 309
 Sterculiaceae 308
 Zygophyllaceae 308
 non-flavonoids 50
 nonpeptidic BACE1 inhibitors 94
 non-steroidal anti-inflammatory drugs (NSAIDs) 163
 non-transformed murine mammary epithelial cells (NMuMG) 20
 Nordihydroguaiaretic acid (NDGA) 164
N-retinyl-*N*-retinylidene ethanolamine 237
- o**
 obovatol 120
 Ochrolifuanine E 116
 ω -hydroxylation 170
Origanum vulgare 142
Orthosiphon stamineus 140
- p**
 Palmerolide A 7
 pancreatic lipase inhibitory effects 140
 Papaveraceae 303
 passive targeting 11
 pelargonidin 141
Pelargonium graveolens 142
Petrosaspongia nigra 81
 peptide inhibitors 121
P. falciparum dihydrofolate reductase (*Pf*-DHFR) 277
P. falciparum lactate dehydrogenase (*Pf*-LDH) 277
P. falciparum purine nucleoside phosphorylase (*Pf*-PNP) 277
Phaseolus vulgaris 211
 phenol acids 105–106

- phenolic acids
 hypoglycaemic natural
 compounds 141
- phenolic compounds, ACE
 inhibition 50–58
- phospholipase A₂ (PLA₂) inhibitors
 bacteria and protozoa 70
 calcium-dependent sPLA₂ 70
 eicosanoids 71
 5-hydroperoxyeicosatetraenoic
 acid 72
 role of 71
 sPLA₂ 71
- sponge-derived metabolites
 anti-psoriasis sesquiterpene
 hydroquinone avarol 82
 Aplysilla 83
 bioactive pyridinium
 alkaloids 81
 bolinaquinone 82
 Cacospongia mollior 78
 cacospongionolide B 82
 cacospongionolide E 82
 difurano-sesterterpenes 83
 Dysidea sp. 81
 furanosesterterpene 83
 Luffariella 73
 manoalide 73
 sesquiterpene lactone
 cavernolide 82
 terpenoids 73
- phospholipase A₂ (PLA₂) inhibitory
 natural products 164
- C-phycoyanin 183
- pericidins 230
- Piper auritum* 147
- piperine 176–177
- Plasmodium falciparum*
 DHFR and TS inhibitors 286–290
 falcipain (FP-2) inhibitors 278–284
 hypoxanthine-guanine-(xanthine)
 phosphoribosyltransferase
 inhibitors 290
 incidence 277
 purine nucleoside phosphorylase
 inhibitors (PNP) 284–286
 target based drug discovery 277
- polyether macrolide halichondrin
 B 259
- polyhydroxylated compounds 124
- polymer nanoparticles 10
- polyphenols 108
- polysaccharides and
 polysaccharopeptides 212
- prenylated flavanones 98
- prohibitin inhibitors 34
- protease enzymes
 β-secretase 1 (BACE1)
 inhibitors 30
 cathepsin inhibitors 28–30
 falcipain inhibitors 27
 serine protease inhibitors 24–26
- proteases and Protease inhibitors 211
- proteasome inhibitors 23
- protein kinase C (PKC) 256
- protein kinase C modulators 30–31
- Pseudopterosin A 85
- Psoralea corylifolia* 102
- Punica granatum* 151
- purine nucleoside phosphorylase
 inhibitors (PNP) 284–286
- pyranocoumarins 114
- pyrimethamine (PYR) 290
- q**
- quaternary protoberberine
 alkaloids 304
- quercetin 141, 177
- quinolizidine alkaloids 149
- r**
- ribonucleases 212
- renin–angiotensin–aldosterone
 system 46–47
- resveratrol 178
- reverse transcriptase inhibitors
 alkylsalicylic acids and bilobols 212
 antifungal proteins 210
 cathelicidins 210
 defensins and defensin-like antifungal
 peptides 210
 HIV-1 protease inhibitor 213
 illimaquinone 212
 laccases and ribonucleases 212

- reverse transcriptase inhibitors (*contd.*)
 lectins 211
 polysaccharides and
 polysaccharopeptides 212
 RNase H 213
 ribosome-inactivating proteins
 (RIPs) 209–210
 RNase H 213
 Rosmarinic acid 120, 142
 rotenone 228
Russula paludosa 212
 Rutaceae 302
 rutin 141
- S**
- saccharides 121
Salinispora tropica 264
 salinoporamide A, a
 γ -lactam- β -lactone 6
 salsalate 12
Sanguisorba tenuifolia 146
 santacruzamate A 22
Sarcococca hookeriana 305
 scalaradial 182
Scutellaria baicalensis 95
Senecio stabianus 143
 serine protease inhibitors 24–26
Sesamum indicum 144
 sesquiterpene lactones (SLs) 180
 sesterterpenes cladocoran A 85
 sesterterpenes cladocoran B 85
Shisandra chinensis 123
 silibinin 178
Silybum marianum 178
Skimmia laureola 302
Smenospongia cerebriformis 116
 sodium channels modulators 35
 6,6-spiroacetal 2
Spirulina platensis 183
 squamous cell carcinoma (SCC) 169
 Sterculiaceae 308
Stereocaulon alpimum 163
 Steroidal alkaloids 305
 stilbenes and derivatives 110–112
Streptomyces hygroscopicus 12
 strobilurins 240
 structure-activity relationships
 (SARs) 146
 studies 8, 286
 Stypoldione 85
 suffruticosol B 110
 sugiol 179
 sulfonamide chalcones 101
 sulforaphane 174
 supercritical fluid chromatography
 (SFC) 9
 symplocin A 29
Syzygium 144
- t**
- Tacrine (Cognex) 298
 tamoxifen 244
 tannic acid 54
 tannins 106–107
 ellagitannins 150
 targeting strategies 11
 tasiamide B 30, 121
 temozolomide (TMZ)-resistant
 gliomas 244
 Tenuigenin 123
 terpenes 118–120
 terpenoids 179
 hypoglycaemic natural
 compounds 142–147
 tertiary carbinamines 94
 tetracyclic diterpene phomactins A 85
 tetrapetalone A 183
 2-thionosparteine 149
 thymidylate synthase (TS)
 inhibitors 286–290
 TongLuoJiuNao (TLJN) 123
 trabectedin 6
Tragia involucrata 147
 transcription-coupled nucleotide repair
 mechanisms (TC-NER) 258
 Trastuzumab-DM1 11
 1,3,5-triazine-4-aminoquinoline
 conjugates 288
 3,5-trihydroxybenzoic acid 4, 175
Tripterygium wilfordii 180
 triptolids 180–181
 triterpenoid saponins 146

trypsin inhibitors 211
20-hydroxyeicosatetraenoic acid
 (20-HETE) 170
type 1 diabetes (T1DM) 135
type 2 diabetes (T2DM) 135

U

uridine phosphorylase (UP)
 inhibitors 284
ursolic acid 181–182
US Food and Drug Administration
 (FDA) 1

V

vanillic acid 141
vescalagin 151

voltage-gated sodium channels
 (VGSCs) 35
vasoconstriction-volume model 48

W

Withania somnifera 152

X

xanthones 104

Z

ziconotide 6, 261
zileuton 163
Zygogynum pancheri 143
Zygophyllaceae 308

